arrow
M

Mariangela Torniai

Marche Polytechnic University
H指数:26
被引数:1,790

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
2024-10-011
OA
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

基于药物的评分对接受一线免疫治疗的晚期非小细胞肺癌患者的预测能力

2021-06-0124
OAAI
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

抗生素治疗和其他药物对一线pembrolizumab与细胞毒性化疗治疗的非小细胞肺癌患者肿瘤学结局的差异影响

2021-04-0797
OAAI
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

在PD-L1表达 ≥ 50% 的NSCLC患者的大型真实队列中,派姆单抗的免疫相关不良事件及其与临床结局的关系

2020-11-0163
OAAI
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study
2020-07-0151
OAAI
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
2019-11-1523
OAAI
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study
2019-09-2714
OAAI
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

二甲双胍使用与接受依维莫司和/或生长抑素类似物的糖尿病和胰腺神经内分泌肿瘤患者的无进展生存期有关

2018-08-0161
OAAI